ArticleMolecular therapy. Nucleic acids2022
Identification and characterization of a MAPT-targeting locked nucleic acid antisense oligonucleotide therapeutic for tauopathies.
Open access · goldAbstract read
In one paragraph
Article in Molecular therapy. Nucleic acids, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Tau Ablation Rewires Brain Cell Programs in Health and Restores Function in Disease.bioRxiv : the preprint server for biology · 2026Article
- Unraveling and controlling late-onset neurotoxicity of antisense oligonucleotides through strategic chemical modifications.Molecular therapy. Nucleic acids · 2025Article
- Transferrin-Functionalized Liposomes Enhance MAPT-ASO Transport Across a 3D Blood-Brain Barrier Microvascular Network Model.International journal of molecular sciences · 2025Article
- Pathological Disulfide Bond Crosslinking: Molecular Insights into Amyloidogenesis and Diseases Progression.Chembiochem : a European journal of chemical biology · 2025Review
- Biologics as Therapeutical Agents Under Perspective Clinical Studies for Alzheimer's Disease.Molecules (Basel, Switzerland) · 2025Review
- Axonal tau reduction ameliorates tau and amyloid pathology in a mouse model of Alzheimer's disease.Translational neurodegeneration · 2025Article
- Immunization targeting diseased proteins in synucleinopathy and tauopathy: insights from clinical trials.Translational neurodegeneration · 2025Review
- MAPT mutations in amyotrophic lateral sclerosis: clinical, neuropathological and functional insights.Journal of neurology · 2025Article
- Molecular insights into regulatory RNAs in the cellular machinery.Experimental & molecular medicine · 2024Review
- Novel avenues of tau research.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Review
- Treatability of the KMT2-Associated Neurodevelopmental Disorders Using Antisense Oligonucleotide-Based Treatments.Human mutation · 2024Review
- TMEM106B reduction does not rescue GRN deficiency in iPSC-derived human microglia and mouse models.iScience · 2023Article
- Lipid nanoparticle delivery limits antisense oligonucleotide activity and cellular distribution in the brain after intracerebroventricular injection.Molecular therapy. Nucleic acids · 2023Article
- Tau; One Protein, So Many Diseases.Biology · 2023Review
- Implications of Tau Dysregulation in Huntington's Disease and Potential for New Therapeutics.Journal of Huntington's disease · 2023Review
- A potential therapeutic approach for tauopathies.Molecular therapy. Nucleic acids · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 4 institutions in 3 countries.
Amy EastonBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Marianne L JensenRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Copenhagen, Hørsholm DK 2970, Denmark.
Congwei WangRoche Pharma Research and Early Development, Neuroscience and Rare Disease Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.
Peter H HagedornRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Copenhagen, Hørsholm DK 2970, Denmark.
Yuwen LiBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Michael WeedBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Jere E MeredithBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Valerie GussBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Kelli JonesBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Martin GillBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Carol KrauseBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Jeffrey M BrownBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Lisa HunihanBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Joanne NataleBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Alda FernandesBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Yifeng LuBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Joe PolinoBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Mark BookbinderBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Greg CadelinaBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Yulia BenitexBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Ramola SaneBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
John MorrisonBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Dieter DrexlerBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Stephen E MercerBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Charlotte BonRoche Pharma Research and Early Development, Neuroscience and Rare Disease Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.
Nikhil J PandyaRoche Pharma Research and Early Development, Neuroscience and Rare Disease Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.
Ravi JagasiaRoche Pharma Research and Early Development, Neuroscience and Rare Disease Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.
Tai-Hsien Ou YangRoche Pharma Research and Early Development, pREDi Data Science, Roche Innovation Center New York, Little Falls, NJ 07424, USA.
Tania DistlerRoche Pharma Research and Early Development, Neuroscience and Rare Disease Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.
Fiona GrüningerRoche Pharma Research and Early Development, Neuroscience and Rare Disease Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.
Michael MeldgaardRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Copenhagen, Hørsholm DK 2970, Denmark.
Marco TerrignoRoche Pharma Research and Early Development, Neuroscience and Rare Disease Discovery and Translational Area, Roche Innovation Center Basel, 4070 Basel, Switzerland.
John E MacorBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Charles F AlbrightBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
James LoyBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Anja M HoegRoche Pharma Research and Early Development, Therapeutic Modalities, Roche Innovation Center Copenhagen, Hørsholm DK 2970, Denmark.
Richard E OlsonBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Angela M CacaceBristol Myers Squibb Research and Development, Cambridge, MA 02142, USA.
Bristol-Myers Squibb (United States) · USRoche (Switzerland) · CHRoche (Denmark) · DKLa Roche College · US
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tau is a microtubule-associated protein (
Indexed as
antisense oligonucleotidescynomolgus monkeyintrathecallocked nucleic acidsMAPTMT: oligonucleotides: therapies and applicationsneurodegenerationtautauopathies
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.